Sage Therapeutics Inc (SAGE)

O firmie

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company is targeting CNS indications where patient populations are easily identified, acute treatment is typically initiated in the hospital setting, clinical endpoints are well-defined, and development pathways are feasible. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is developed as an adjunctive IV therapy for the treatment of status epilepticus patients whose seizures have not resolved after treatment with traditional therapies.